Neurological, Psychiatric, and Multisystemic Involvement of Fragile X Syndrome Along With Its Pathophysiology, Methods of Screening, and Current Treatment Modalities

Raunak Ranjan 1, Saumya Jha 1, Priyadarshi Prajjwal 2, Ansh Chaudhary 3, Pragya Dudeja 4, Neel Vora 5, Mohammed A. Mateen 6, Mohammed A. Yousuf 7, Bhupendra Chaudhary 8

1. Internal Medicine, Bharati Vidyapeeth University Medical College, Pune, IND 2. Neurology, Bharati Vidyapeeth University Medical College, Pune, IND 3. Internal Medicine, Kasturba Medical College, Manipal, Manipal, IND 4. Internal Medicine, B.J. (Byramjee Jeejeebhoy) Medical College, Ahmedabad, IND 5. Internal Medicine, Shadan Institute of Medical Sciences Teaching Hospital and Research Centre, Hyderabad, IND 6. Neuroscience, Jawant Rai Speciality Hospital, Meerut, IND

Corresponding author: Raunak Ranjan, raunakranjan63@gmail.com

Abstract

Fragile X syndrome (FXS) is a hereditary disease that predominantly leads to intellectual disability (ID) in boys. It is the second prominent cause of ID, which manifests as a result of the atypical development of the cytosine-guanine-guanine (CGG) region. This irregular extension of the CGG region gives rise to methylation and silencing of the fragile X mental retardation 1 (FMR1) gene, causing a loss of the fragile X mental retardation 1 protein (FMRP). This reduction or loss of FMRP is the main cause of ID. It has a multisystemic involvement showing neuropsychiatric features such as ID, speech and language delay, autism spectrum disorder, sensory hyperarousal, social anxiety, abnormal eye contact, shyness, and aggressive behaviour. It is also known to cause musculoskeletal symptoms, ocular symptoms, cardiac abnormalities, and gastrointestinal symptoms. The management is challenging, and there is no known cure for the disease; hence an early diagnosis of the condition is needed through prenatal screening offered to couples with familial history of ID before conception. The management rests on non-pharmacological modalities, including applied behaviour analysis, physical therapy, occupational therapy, speech-language therapy, and pharmacologic management through symptomatic treatment of comorbid behaviours and psychiatric problems and some forms of targeted therapy.

Categories: Genetics, Internal Medicine, Neurology
Keywords: autism spectrum disorder (asd), fragile x mental retardation 1, fragile x syndrome, intellectual disability (id), autism, connective tissue disorder(ctd), neuropsychiatric, cgg repeats, fmr1 gene

Introduction And Background

Bell and Martin, in 1945, put forward a noteworthy investigation in the field of genetics by recognizing Fragile X syndrome (FXS) as a genetic disorder that is an underlying cause of intellectual disability (ID). FXS, also called Martin-Bell syndrome, is prompted by a repeated sequence of three nucleotides on the X chromosome, known as a trinucleotide repeat [1]. Further research in 1991 established the association of the specific fragile region on the X chromosome with ID. Lubs initially made this finding in 1969 by observing this relationship in three families [2,3]. FXS, a genetic disorder known to cause ID, results from a trinucleotide repeat on the X chromosome and is now regarded as the principal hereditary cause of ID in boys, following Down syndrome accounting for 2.4% of all ID cases [4,5]. According to estimates, there are about 1:5000 males, and 1:6000 females affected globally. The disease has multisystemic implications and is known to cause neuropsychiatric, ocular, and gastric symptoms. In addition, it shows characteristics similar to the connective tissue disorder spectrum.

Methods

Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines guided establishing this systematic review to optimize its rigour and comprehensiveness (Figure 1).
Study Search and Criteria of Selection

Searches were conducted on PubMed Central, PubMed, and Science Direct libraries of articles published between January 1943 and January 2022, and relevant references were retrieved. The search terms “Fragile X mental retardation 1 (FMR1) gene”, “Cytosine-guanine-guanine (CGG) repeats”, “Autism spectrum disorder”, and “Fragile X syndrome (FXS)” were used, and the obtained studies were assessed for suitability. Articles written in the English language, research focusing on children, adolescents, and adults, and literature pertaining to the topic of discussion were taken into consideration. Relevant studies were then broadly investigated regarding the research in question using title and abstract. Geriatric-based research, articles in languages other than English, papers published over 79 years ago, and unrelated studies were excluded.

Review

Pathophysiology

The fragile X mental retardation 1 (FMR1) gene is located on Xq27.3 and undergoes an increase of CGG repeats (>200), which is the cause of FXS. The aberrant CGG expansion causes the FMR1 gene to be methylated and transcriptionally silenced, which causes fragile X mental retardation 1 protein (FMRP) to be reduced or lost. FMRP is a protein that travels to and from the nucleus and may be involved in the nuclear export of messenger ribonucleic acids (mRNAs). Immature axons, growth cones, dendritic spines, and mature dendrites, all contain FMRP. Arc and MAP1b are two proteins whose translation is structured by FMRP, which are known to regulate α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor endocytosis and, thereby, synaptic function. Due to FMRP deficiency, there is a loss in synaptic growth and plasticity. Formation of long, thin, juvenile dendritic spines occurs, which can impair cognitive and learning abilities [6]. The FMR1 gene can be classified into one of four groups (determined by the number and redundancy of CGGs): The most frequent is 6–44 CGG repeats in humans; 45–54 CGG repeats are called...
often results in conductive hearing loss
include convergence insufficiency and palpebral ptosis
are also reported), whereas nystagmus is rarely spotted (5-13%). Other noticeable ocular characteristics
40%, and refractive errors 17-59% (commonly, astigmatisms and hyperopia, while sporadic events of myopia
least 25% of children with FXS and a higher proportion of adults with FXS. Among them are strabismus 8-
investigated. Hypotonia and connective tissue anomalies may be responsible for some gastrointestinal issues
The functioning of the gastrointestinal (GI) system in individuals with FXS has yet to be thoroughly

gastroesophageal reflux, affect nearly 30% of patients [27-29]. The hallmark of the syndrome
is undoubtedly the neurologic/neuropsychiatric presentation. Still, FXS also relates to several medical issues
that may or may not be present; when they are present, they can exacerbate the phenotype of patients and
make clinical management more challenging.

It has been evident that FXS and connective tissue disorder (CTD) spectra share some characteristics
since the ailment was first reported. The prevalence of connective tissue symptoms suggests the existence of an
abnormality in the underlying connective tissue, similar to what is observed in CTDs, even if a specific
connective tissue abnormality such as Ehlers-Danlos syndrome (EDS) or Marfan syndrome (MFS) has not
been demonstrated yet. Skin can be soft [27-29], and joint hypermobility, which primarily affects tiny joints
(mainly metacarpal-phalangeal joints), exists in nearly half of the patients [29]. Flat feet, a high-arched palate, scoliosis, and pectus excavatum are examples of skeletal symptoms [30].

In FXS patients, the heart is also influenced by heightened connective tissue fragility, which leads to cardiac aberrations comparable to those with CTDs. Aortic root dilatation, presenting in about one-fourth (25%) of the patients, and mitral valve prolapse (MVP), affecting 3-50% of patients, are common conclusions [31]. Additional findings include parasympathetic vagal tone reduction and hyperarousal (i.e., a higher heart rate). Adult FXS patients (older than 40 years) frequently experience the same cardiovascular issues as the general population in their age group, including cardiac rhythm difficulties (24.2%) and hypertension (24.2%) [32].

The functioning of the gastrointestinal (GI) system in individuals with FXS has yet to be thoroughly
investigated. Hypotonia and connective tissue anomalies may be responsible for some gastrointestinal issues
associated with this syndrome, including gastro-oesophageal reflux, loose stools, and constipation. About 30.6% of FXS-presenting individuals aged 40-71 report digestive issues [32]. Ocular signs are reported in at least 25% of children with FXS and a higher proportion of adults with FXS. Among them are strabismus 8-40%, and refractive errors 17-59% (commonly, astigmatisms and hyperopia, while sporadic events of myopia are also reported), whereas nystagmus is rarely spotted (5-13%). Other noticeable ocular characteristics include convergence insufficiency and palpebral ptosis [33-36]. Recurrent otitis media in children with FXS often results in conductive hearing loss [37]. Since these individuals already have limited expressive
language abilities, it is crucial that any potential otologic issues are treated urgently to prevent impeding their ability to speak more clearly [38].

**Differential diagnoses**

**Sotos Syndrome**

Sotos syndrome is a genetic disorder that presents with abnormal growth developments such as peculiar facial characteristics, overgrowth in childhood, and compromised development of cognitive and motor abilities. Other associated attributes include immoderate height and an excessively large cranial circumference. Furthermore, individuals with Sotos syndrome may exhibit phenotypic similarities with FXS-affected patients, such as ASD, ADHD, phobias, obsessive-compulsive behaviours, impulsive behaviours, and tantrums.

**Prader-Willi Syndrome**

Prader-Willi syndrome (PWS) is a genetic disorder caused by a deletion or abnormality in a specific region of chromosome 15. It is a rare condition, affecting approximately one in 10,000 to 30,000 individuals worldwide. The symptoms of PWS can be physical, cognitive, and behavioural, and they can vary widely from person to person.

**Klinefelter Syndrome**

Klinefelter syndrome is a genetic disorder that affects males and is caused by an extra X chromosome. It is estimated to affect approximately one in 500 to 1,000 male births. Individuals with Klinefelter syndrome may experience various physical, cognitive, and behavioural symptoms, including infertility, reduced muscle mass, increased body fat, and learning disabilities. Treatment for Klinefelter syndrome typically involves testosterone replacement therapy and may include educational support for learning challenges.

**Rett Syndrome and Angelman Syndrome**

In the differential diagnosis of FXS, Rett syndrome and Angelman syndrome must be taken into account, irrespective of the fact that their clinical presentation may differ from that of FXS. Common characteristics between these syndromes and FXS include ID, language impairments, and autistic behaviour. Array comparative genomic hybridisation (CGH) may be carried out to rule out the possibility of cytogenetic rearrangements causing ID. When genetic testing proves inconclusive, isolated ID, autism, or ADHD should be deliberated as probable diagnoses [39].

**Screening and diagnosis**

**Prenatal FMR1 testing**

As mentioned above, FXS molecular testing is often conducted postnatally on peripheral blood lymphocytes (when the necessary clinical features are present). Furthermore, it is possible to perform prenatal testing for FXS by using long-range-polymerase chain reaction (LR-PCR) techniques on DNA obtained from amniocytes or chorionic villi. According to the latest guidelines from the American College of Medical Genetics (ACMG) and the American Congress of Obstetricians and Gynecologists (ACOG), couples who have a personal or family history of any of the following should be provided FMR1 prenatal testing: unexplained ID or developmental delay, FXS- or FX-related disorders, isolated cognitive impairment, isolated cerebellar ataxia with tremor, idiopathic familiar primary ovarian insufficiency or elevated follicle-stimulating hormone (FSH) at age <40 years, and autism.

Many geneticists recommend that antenatal screening for FXS be made available to all women who desire it, regardless of their personal or family history, due to the high FXS incidences in public [40]. The test should be offered to couples who desire FXS screening before conception, giving the pair a chance to make informed reproductive decisions. The parents must also provide pertinent information regarding their health.

**Advanced Diagnostic Methods**

Over time, the diagnosis of FXS has changed. It was initially based on the cytogenetic analysis of fragile X (FRAXA)’s existence in peripheral blood lymphocytes (G-banding) (Figure 2). However, it was restricted due to issues including the procedure’s length, difficulty in interpretation, and requirement for specific technical abilities.
To overcome the constraints of previously practised testing procedures, fluorescence in situ hybridisation (FISH) has been established as an alternate method for distinguishing FXS. This method uses DNA probes labelled with fluorescent dyes to identify the exact position of genetic material, thereby increasing the detection rate of FXS. The use of DNA Southern blot analysis for \textit{FMR1} gene testing has been recognized as the ideal method for cytogenetic analyses, as it helps identify all \textit{FMR1} alleles, including normal, permutation (PM), and full mutation (FM), as well as determining the methylation status of the \textit{FMR1} promoter region. However, this technique is likewise complex and resource-intensive as its predecessors, rendering it a complicated and costly procedure.

The current standard for FXS molecular analysis is PCR combined with Southern blot analysis \cite{42, 43}. Methylation status and the number of CGG repeats can be assessed with the help of a standard PCR and Southern blot analysis. Calculating the number of CGG repeats on the X chromosome enables precise FXS risk assessment and offers FXS families information about their reproductive possibilities. It is important to note that relying solely on the amount of CGG repeats will pick up fewer than 1\% of FXS produced by deletions or missense mutations in the \textit{FMR1} gene. Potential ‘non-CGG repeat’ causes of FXS could be found using precise measurements of the FMRP level and sequencing of the \textit{FMR1} gene \cite{44}. However, it could only identify alleles with up to 160 and 300 repetitions in females and 300 repeats in males, respectively, failing to detect massive CGG expansions \cite{45, 46}.

The triplet primed PCR (TP-PCR) is a relatively latest method for detecting \textit{FMR1} alleles, which involves the use of three primers, including a forward primer situated in the upstream CGG region, a second primer that covers both the CGG repeat and the adjacent unique sequence, and a third primer that is complementary to the \textit{FMR1} triplet repeat region. Using TP-PCR, it is possible to amplify the full-length \textit{FMR1} allele and the CGG triplets together in a single PCR reaction. The number of CGG repeats is then assessed by evaluating the size of the PCR products through capillary electrophoresis. TP-PCR has gained popularity in being regarded as the most accurate and reliable method for the diagnosis of FXS. Furthermore, the methylation-sensitive long-range PCR (MS-LR-PCR) kit can be used to perform CGG methylation testing as a follow-up analysis in the diagnostic process to investigate the silencing of FMRP \cite{47}.

\textbf{Treatment}

Treatment can be classified into three categories.

\textit{Non Pharmacological}

Physical therapy (PT), occupational therapy (OT), speech-language therapy (SLT), and ABA are essential non-pharmacological interventions (Figure 3) for FXS in dealing with motor and speech-language problems and social communication skills in those with comorbid ASD. Behavioural therapy (parent training) can
assist children and teens with behavioural problems like aggression, hyperactivity, and tantrums. Cognitive
behavioural therapy (CBT) can play a role in facilitating women and high-functioning males with anxiety,
ADHD, social challenges, and depression through individual therapy [48,49]. SLT and OT are the two most
preferred interventions for FXS-afflicted children [50]. SLT is widely used to treat FXS children and address
their delayed communicative development.

![Image: An overview of non-pharmacological treatment modalities in FXS](Image Source: Protic et al., 2022 [49])

For FXS individuals, OT tackles the sensory integration challenges common among the population. OT also
aims at improving sensory processing, sensorimotor abilities, and play engagement for young children while
encouraging independence and job readiness for teens. Research has revealed that vocational training
programs emphasizing life skills such as community involvement, computer skills, financial management,
and interpersonal interactions can provide long-term benefits by offering improved satisfaction and stable
employment [51-53]. Parent-implemented language intervention (PILI) strives to enhance communication
and language skills by teaching parents how to incorporate responsive skills in interacting with their child. It
attempts to help promote language development. Such intervention can be adopted in the home
environment and is designed to be integrated into the child's daily activities. PILI effectively improves
language skills in children with FXS and is considered a promising approach for addressing the language
challenges that often accompany the disorder [54].

ABA is a different intervention used with FXS kids, notably those with ASD. The premise underlying ABA is
that positive actions should be reinforced. The Early Start Denver Model (ESDM) is a therapeutic approach
comprising principles of ABA, focusing on refining language skills and social interactions in young children
between one and three years of age in a realistic home setting. PT is also a generally adopted intervention
for children with FXS [50]. FXS patients experiencing difficulty with walking and balance may receive
recommendations from physical therapists for assistive devices, such as strollers for stability or orthotics to
correct foot pronation [55]. Physical activity is linked to enhanced attention and cognitive control in
developing children [56]. Exercise causes a rise in brain-derived neurotrophic factor (BDNF), crucial for
brain development and neuroplasticity, which may help explain this phenomenon [57]. Elevated anxiety
levels in kids with FXS can be treated with CBT, a talk therapy that has been proven useful in regulating
emotions. Music therapy has also increased self-expression and communication abilities in children with
FXS [58].
**Psychopharmacological**

Anxiety is a common issue among those with FXS. Sertraline, a selective serotonin reuptake inhibitor (SSRI), is an efficacious treatment modality for this condition. SSRIs prevent the presynaptic reuptake of serotonin, thereby increasing serotonin levels in the synapse, which play a crucial role in regulating mood in the central nervous system. Another antidepressant known to elevate noradrenergic and dopaminergic neurotransmission is bupropion, which blocks reuptake.

People with FXS may exhibit aggressive behaviour, involve in self-harm, and display violent outbursts or “meltdowns,” particularly during their teenage years. Risperidone and aripiprazole are two types of atypical antipsychotics that can effectively address symptoms of aggression and meltdowns, which often accompany anxiety in FXS. They work by activating serotonergic and dopaminergic receptors in the brain.

ADHD is categorized by continuous episodes of distractibility, hyperactivity, and/or impulsivity that are more different or upsetting than children of the same age and trigger complications in multiple settings. For children aged six years and above with ADHD, stimulant medication is the first line of treatment. These drugs enhance the levels of norepinephrine and dopamine in the prefrontal cortex, which are vital for improving task motivation, attention, and impulse control. Moreover, clonidine and guanfacine (alpha 2-adrenergic receptor agonists) may also be advantageous in handling ADHD symptoms. Alternative treatments may be considered for individuals who either do not respond to or cannot tolerate stimulant medications, such as young children under the age of years. Clonidine and guanfacine (alpha 2-adrenergic receptor agonists) can improve attention and provide a comforting effect on hyperarousal by enhancing norepinephrine levels in the prefrontal cortex. It can be particularly helpful for those with FXS.

Sleep issues are predominant among FXS sufferers. It is characterized by sleep difficulty ranging from 27% to 77% in individuals with FXS. Melatonin is regarded as the most effective treatment for this illness. The hormone is released from a pineal gland under typical environments at night, accelerates the sleeping process, and increases the length of nighttime sleep. Moreover, it exhibits neural plasticity and antioxidative properties, which may aid memory and learning. Nevertheless, a few side effects of melatonin have also been reported, such as daytime sleepiness and nausea.

In those with FXS, seizures are effectively managed by a single anticonvulsant. Several anticonvulsant drugs are used in the course of treatment. For controllable side effects, levetiracetam and oxcarbazepine are regularly used as first-choice treatments. Substitute medications like valproic acid and lamotrigine may also be effective, particularly for those with generalized seizures. However, due to the severity of their side effects, phenytoin, phenobarbital, and gabapentin should be avoided.

**Targeted Therapy**

Over the past decade, much effort has been devoted to introducing specific treatments for FXS. Currently, two approaches are being explored as potential major treatments for FXS: Reactivating the damaged gene is one option, and making up for FMRP’s absence is another. The hypothesis describing how excessive translation in FXS, which is typically triggered by stimulation of the mGluR or another Gq-coupled receptor (when FMRP is absent), leads to cognitive and behavioural manifestations and has provided multiple potential sites for targeted therapy (Table 1 and Table 2). However, these techniques are constantly being developed, and there is currently no known cure for FXS.
Reversal of Phenotypic features

<table>
<thead>
<tr>
<th>dFMR1 mutant fly</th>
<th>FMR1 KO mouse</th>
<th>FXS-carrying humans</th>
</tr>
</thead>
</table>

Halt the external pathway of translational signalling:

- mGluR5 inhibition; Fenobam, STX107, MPEP, RO4917523, AFQ056; Inhibition of mGluR5 by lowering mGluR5 receptors genetically

- Courtship behaviour: Instant recall and temporary memory; Survival on glutamate-rich food; Odour-shock memory; Body revealing mushroom appearance

- Rupture of epileptiform; Hyperactivity in an open-field environment; Convulsive seizures produced by a high-frequency sound; dendritic spine morphology; Prepulse inhibition; Amygdala mEPSP frequency; Marble burying; Plasticity in the visual cortex; Extinction of passive avoidance; Density in dendritic spine; Abnormally high protein synthesis

STX107-Phase I completed; Fenobam- Phase IIa (single-dose); PPI alleviated, and anxiety was reduced; AFQ056 - Phase IIb; improvement in patients exhibiting complete methylation; phase III trial is commenced; RO4917523 - phase II trial underway

Halt the internal pathway of translational signalling:

- GSK3β inhibition using AR-A014418 or SB-216763; PAK inhibition through genetic reduction of PAK; PI3K inhibition using LY294002; ERK/MEK inhibition using SL327, -Lithium is used to inhibit GSK3β and reduce the short-term turnover of P.

- Dendritic spine morphology; Open-field hyperactivity; Audiogenic seizures; Learning and anxiety deficits in the elevated plus maze; Elevated zero mazes; Passive avoidance; Social interaction defect; Anxiety during social interaction; Impairment in cortical LTP; Behavioral redundancy

Behavioural improvement was observed in an open-label trial, with improvement in some adaptive skills and verbal memory; Normalisation of ERK biomarker

<table>
<thead>
<tr>
<th>TABLE 1: Potential sites for targeted therapy of fragile X syndrome</th>
</tr>
</thead>
<tbody>
<tr>
<td>KO: knock-out; FXS: fragile X syndrome; mEPSP: miniature excitatory postsynaptic potentials; LTP: long-term potentiation; ERK: extracellular signal-regulated kinase</td>
</tr>
</tbody>
</table>

Information from: Berry-Kravis et al., 2011 [(65)]
**Reversal of Phenotypic Features**

<table>
<thead>
<tr>
<th>dFMRI mutant fly</th>
<th>FMR1 KO mouse</th>
<th>FXS-carrying humans</th>
</tr>
</thead>
</table>

**Progress in Translation**

- Prevent the activity of specific proteins regulated by FMRP:
  - Inhibit STEP through genetic reduction of STEP.
  - Inhibit APP/Aβ through antibody or genetic reduction of APP.
  - Inhibit MMP9 with minocycline.

- Stimulate cell-surface AMPA receptors:
  - Ampakines (CX516, CX614)
    - The increase in BDNF levels caused by CX614 leads to reversing impairments in TBS-LTP in the hippocampus.

- Other proteins/synaptic receptors:
  - GABA-B agonists (baclofen, R-baclofen); NMDA Antagonists - Anticholinesterase (donepezil); GABA-A agonists (ganaxolone)
    - Audiogenic seizures are caused by sound, increased activity in open spaces, and burying marbles.
    - Phase II trial of R-baclofen shows improvement in overall function and social and language abilities, particularly in those with more severe social impairments; An open-label trial demonstrated improvement in behaviour and social skills; A small open-label trial of Memantine also showed positive results; An open-label trial of acamprosate manifested improved language; An open-label trial of riluzole normalised ERK; overall improvement was negligible.

**TABLE 2: Potential sites for targeted therapy of fragile X syndrome**

| KO: knock-out; FXS: fragile X syndrome; STEP: striatal-enriched protein tyrosine phosphatase; APP: amyloid precursor protein; MMP9: matrix metalloproteinase 9; AMPA: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; FMRP: fragile X mental retardation 1 protein; BDNF: brain-derived neurotrophic factor; TBS: Townes-Brocks syndrome; LTP: long-term potentiation; GABA: gamma-aminobutyric acid; NMDA: N-methyl-D-aspartate; ERK: extracellular signal-regulated kinase |
|---|---|---|
| **GABA-B agonists** (baclofen, R-baclofen); NMDA Antagonists - Anticholinesterase (donepezil); GABA-A agonists (ganaxolone) | The ability to survive on food containing glutamate and memory impairments. | Phase II trial of R-baclofen shows improvement in overall function and social and language abilities, particularly in those with more severe social impairments; An open-label trial demonstrated improvement in behaviour and social skills; A small open-label trial of Memantine also showed positive results; An open-label trial of acamprosate manifested improved language; An open-label trial of riluzole normalised ERK; overall improvement was negligible. |

**Limitations of the study**

Our thorough investigation has a few limitations that need to be acknowledged and recorded. Limited research and clinical trial data hinder the development of effective treatments for targeted therapy. Since this is a fairly new approach and many studies are still being conducted using it, there is a shortage of documentation available. Another key aspect to consider when selecting the studies was free full-text availability. Last but not least, there is a risk of information bias because of increased global interest in the study's subject.

**Conclusions**

FXS is a true syndrome in that it affects multiple body systems and presents with varied clinical features. FXS poses a disorder with a huge burden on the child and his family, both socially and financially. Due to the majority of its clinical features being in the same domain as diseases such as Angelman syndrome and Rett syndrome, Klinefelter syndrome, Prader-Willi syndrome, and Sotos syndrome, a clinician should always keep his mind open to the possibility of FXS in an intellectually disabled child. Over the years, numerous techniques for prenatal testing and early diagnosis have been developed. Non-pharmacological treatments...
addressing gross and fine motor, speech-language, and social-communication deficiencies have proved effective. With ongoing clinical trials for targeted management through mGluR5 inhibition, GSK3, and PAK inhibition by genetic reduction, an effort towards curing the disease is being sought to reduce the disease burden.

## Additional Information

### Disclosures

**Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

### References

1. Martin JP, Bell I: A pedigree of mental defect showing sex-linkage. J Neurol Psychiatry. 1945, 6:154-7. 10.1136/jnp.6.1.154


